Close Menu

NEW YORK – The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for atezolizumab (Roche's Tecentriq) combined with chemotherapy as a first-line treatment of metastatic non-small cell lung cancer without EGFR mutations or ALK rearrangements.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Oct
23

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries.